Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress
Cerus Corporation (Nasdaq: CERS) announced today a company-sponsored lunch symposium and a selection of abstracts at the International Society of Blood Transfusion (ISBT) 39th International ISBT Congress, taking place in Kuala Lumpur, Malaysia, from June 20 through June 24, 2026. Transfusion medicine experts and professionals from around the world are expected to attend the ISBT Congress.
“We look forward to highlighting how blood centers around the world are leveraging INTERCEPT technology to strengthen blood safety, improve operational efficiency and enhance patient care,” said Christian Boutemy, vice president, international commercial operations at Cerus. “This year’s abstracts reflect the growing body of evidence supporting the INTERCEPT Blood System, alongside valuable real-world experiences from blood centers across Asia. The presentations showcase innovations intended to help optimize operations, including reduced processing times with the LED-based INT200 illuminator and inventory management advantages associated with extended platelet shelf-life, as demonstrated by experience from Thailand. Importantly, an abstract from China draws attention to persistent bacterial contamination risks in platelet components and reinforces the value of a proactive pathogen-inactivation strategy in one of the world’s largest transfusion markets.”
